Behavioral Activation Reduces Pain During Smoking Cessation in Depressed Adults

The Clinical Intersection of Depression, Pain, and Tobacco Dependence

Patients with severe mental illness, including major depressive disorder, face a life expectancy reduction of 10 to 20 years compared to the general population, with respiratory diseases driven by high smoking rates serving as a primary cause of premature mortality [1]. While pharmacological interventions like varenicline and bupropion are effective for cessation in this cohort, they do not address the complex psychological and physical comorbidities that often undermine long-term abstinence [2, 3]. Chronic pain frequently co-occurs with depression and nicotine dependence, creating a cycle of negative affect and physical discomfort that complicates standard treatment protocols [4, 5]. Although lifestyle and behavioral interventions are known to improve health-related quality of life, their specific impact on physical symptoms during the acute withdrawal phase remains under-examined [6]. A new study now investigates how a structured behavioral approach targeting reward processing might alleviate bodily pain during the intensive period of tobacco cessation.

Trial Design and Patient Characteristics

This secondary analysis (a study that uses data previously collected for a different primary research question to explore new hypotheses) evaluated the efficacy of Behavioral Activation Smoking Cessation (BASC) compared to standard behavioral treatment (ST) for reducing bodily pain during the cessation process. The study cohort consisted of 244 adults who smoked cigarettes daily and met the criteria for a lifetime history of major depressive disorder. The participant population had a mean age of 50.1 years and was characterized by a diverse demographic profile, including 57% female and 53% Black participants. By focusing on this specific group, the researchers aimed to determine if a behavioral intervention designed to increase engagement in rewarding activities could mitigate the physical discomfort often reported by patients with comorbid mood disorders during nicotine withdrawal. This approach is particularly relevant for clinicians treating patients who may use nicotine as a maladaptive coping mechanism for both emotional distress and physical symptoms.

Tracking Pain Across the Cessation Timeline

To quantify the physical burden experienced by participants, the researchers utilized the Short-Form Survey (SF-36), a validated instrument designed to measure various domains of health status. In this specific analysis, the bodily pain subscale was used, where lower scores indicate lower levels of pain and interference. By employing this standardized metric, the study provided a consistent framework for clinicians to evaluate how the intensity of physical discomfort fluctuated in response to both the smoking cessation process and the behavioral interventions provided. The researchers randomized participants to receive either the BASC intervention or standard behavioral treatment, which served as the control for behavioral counseling. To account for the role of pharmacotherapy in cessation, these behavioral arms were further paired with either varenicline or a placebo. Clinicians monitored patient progress over a 27 week period, collecting data at baseline (week 1), the target quit date (week 3), and subsequent intervals at weeks 7, 12, and 27.

Significant Pain Mitigation During Active Treatment

To interpret these longitudinal data points, the researchers employed repeated measures analyses (a statistical method used to track how specific variables change within the same group of patients over multiple time points). These analyses demonstrated that the Behavioral Activation Smoking Cessation intervention exerted a significant effect on the trajectory of pain change throughout the treatment period (F(2.75) = 4.38, p = .006). This effect was most pronounced during the critical window between the target quit date at week 3 and the conclusion of the active intervention at week 12. During this interval, participants in the Behavioral Activation Smoking Cessation group experienced a 9.55-point decrease in Short-Form Survey scores, indicating a substantial reduction in bodily pain. In contrast, those receiving standard behavioral treatment showed a negligible 0.86-point decrease in their scores over the same nine week period. By the week 12 end of treatment assessment, the disparity between the two groups remained statistically significant. The Behavioral Activation Smoking Cessation group reported a mean pain score of 19.05, whereas the standard treatment group reported a mean score of 28.83 (p < .001). These data indicate that the behavioral activation protocol resulted in a clinically meaningful reduction in pain relative to standard care during the active 12 week intervention phase.

Clinical Implications for Transdiagnostic Care

The frequent co-occurrence of physical pain and major depressive disorder among individuals who smoke cigarettes presents a complex clinical challenge, as each condition can undermine the success of a cessation attempt. Behavioral activation is a standard evidence-based treatment for major depressive disorder that focuses on increasing a patient's engagement in rewarding activities to improve mood and functioning. The researchers suggest that this therapeutic framework may also reduce physical pain by altering the patient's behavioral response to discomfort and increasing positive reinforcement from their environment. Despite the significant improvements observed during the active treatment phase, the longitudinal data indicate that these benefits may diminish once the structured intervention concludes. At the week 27 follow-up, the researchers found that the initial gap in pain levels between the two study arms had closed. Specifically, there was no significant difference in pain observed between the Behavioral Activation Smoking Cessation group, which reported a mean score of 28.63, and the standard treatment group, which reported a mean score of 31.14 (p = .163). For the practicing clinician, these findings highlight the utility of behavioral activation as a transdiagnostic tool (a clinical method that addresses multiple comorbid conditions through a single integrated treatment protocol). Because the intervention produced a clinically meaningful reduction in pain compared to standard treatment during the 12-week intervention, it offers a viable pathway for managing the physical and psychological distress that often leads to smoking relapse, though additional strategies may be required to sustain these improvements long-term.

References

1. Laguna-Muñoz D, Pata MP, Jiménez-Peinado A, et al. Mortality from respiratory diseases in individuals with severe mental illness: a large-scale systematic review and meta-analysis of pooled and specific diagnoses.. The lancet. Psychiatry. 2025. doi:10.1016/S2215-0366(25)00262-7

2. Bekkering GE, Detraux J, López-López JA, et al. Smoking cessation for people with severe mental illness: systematic review and network meta-analysis.. BMJ medicine. 2026. doi:10.1136/bmjmed-2025-002190

3. Kypriotakis G, Cinciripini PM, Green CE, et al. Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial.. The American journal of psychiatry. 2025. doi:10.1176/appi.ajp.20230855

4. Praecht A, Garvie S, Sorkhou M, MacKillop J, George TP. Tobacco use and impulsivity in people with mental illness: A systematic review.. The American journal on addictions. 2025. doi:10.1111/ajad.70032

5. Aldi GA, Bertoli G, Ferraro F, Pezzuto A, Cosci F. Effectiveness of pharmacological or psychological interventions for smoking cessation in smokers with major depression or depressive symptoms: A systematic review of the literature.. Substance abuse. 2018. doi:10.1080/08897077.2018.1439802

6. Amiri S, Mahmood N, Junaidi S, Khan MA. Lifestyle interventions improving health-related quality of life: A systematic review and meta-analysis of randomized control trials. Journal of Education and Health Promotion. 2024. doi:10.4103/jehp.jehp_1156_23